Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
-
Publication number: 20100093843Abstract: The invention relates to novel nutraceutical and pharmaceutical compositions comprising at least a compound of the general formula (I), wherein R1 and R2 are independently from each other C1-8-alk(en)yl and R3 and R4 are independently from each other hydroxy or C1-8-alkyloxy, as well as to the use of these compositions for the treatment, co-treatment or prevention of joint disorders.Type: ApplicationFiled: September 12, 2007Publication date: April 15, 2010Inventors: Joseph Schwager, Daniel Raederstorff, Goede Schueler
-
Patent number: 7696245Abstract: A compound represented by the following general formula (IA) or (IB) or a salt thereof which specifically traps a zinc ion and emits fluorescence, and is useful as a fluorescent probe for zinc: wherein R1 and R2 represent a hydrogen atom or a group represented by the following formula (A): wherein X1 to X4 represent a hydrogen atom, a 2-pyridylmethyl group, a 2-pyridylethyl group, a 2-methyl-6-pyridylmethyl group, or a 2-methyl-6-pyridylethyl group, provided that at least one is the group except a 2-pyridylmethyl group, and m and n represent 0 or 1, provided that they are not simultaneously 0; provided that R1 and R2 are not simultaneously hydrogen atoms; R3 and R4 represent a hydrogen atom or a halogen atom; R5 and R6 represent a hydrogen atom, an alkylcarbonyl group, or an alkylcarbonyloxymethyl group; and R7 represents a hydrogen atom or an alkyl group.Type: GrantFiled: January 30, 2004Date of Patent: April 13, 2010Assignees: Sekisui Medical Co., Ltd.Inventors: Kensuke Komatsu, Tomoya Hirano, Kazuya Kikuchi, Tetsuo Nagano
-
Publication number: 20100087422Abstract: A method is described for treating attention deficit hyperactivity disorder (ADHD), by administering to the individual an anti-epileptic mood stabiliser at a dose which is sub-therapeutic for mood stabilisation, optionally in combination with a psychostimulant. Also described is a method of improving reading comprehension and/or fluency in an individual suffering from learning difficulties which method comprises administering to the individual an anti-epileptic mood stabiliser.Type: ApplicationFiled: February 7, 2008Publication date: April 8, 2010Applicant: GOSFORTH CENTRE (HOLDINGS) PTY LTDInventor: Philip Bird
-
Publication number: 20100087518Abstract: The present invention provides a process for handling ?9-THC, which comprises preparing a solution of ?9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of ?9-THC in the solvent and solid preparations of ?9-THC.Type: ApplicationFiled: February 19, 2008Publication date: April 8, 2010Applicant: RESOLUTION CHEMICALS LIMITEDInventors: Parveen Bhatarah, Alan Kenneth Greenwood, Derek Mchattie, Jerome Thomas Garfield Carr-Brion
-
Patent number: 7687538Abstract: Compounds and compositions that are salvinorin A and salvinorin B derivatives that demonstrate selectivity and/or potency for the k-opioid receptor (KOR), allowing for their use as medicines, as well as chemical probes (both radiolabeled and cold) for fields utilizing the techniques of radiolabeled binding assays.Type: GrantFiled: July 29, 2005Date of Patent: March 30, 2010Assignees: University of Mississippi, Case Western Reserve UniversityInventors: Jordan Zjawiony, Hesham Fahmy, David Jeremy Stewart, Bryan Roth
-
Publication number: 20100076070Abstract: An administration method is provided, in which a composition comprising a forskolin 1?,9?-carbonate compound is administered to a human subject. According to an embodiment, the forskolin 1?,9?-carbonate compound has a skeletal structure of 8,13-epoxy-1?,6?,7?,9?-tetrahydroxylabd-14-en-11-one. A carbonyl group links the 1-position hydroxy oxygen and the 9-position hydroxy oxygen to one another for forming a carbonate ester ring. Hydrogen is appended to the 6-position hydroxy oxygen. A hydrogen or an acetyl group is appended to the 7-position hydroxy oxygen.Type: ApplicationFiled: November 27, 2009Publication date: March 25, 2010Applicant: BIOTEST LABORATORIES, LLC.Inventor: William J. Roberts
-
Publication number: 20100076069Abstract: Disclosed is an optimal dosing regimen for forskolin to ensure the most optimal pharmacokinetic/pharmacodynamic responses desired in the therapeutic management of open angle glaucoma. The optimal dosing regimen involves the ocular application of 2% forskolin solubilized using randomly-methylated beta-cyclodextrins one drop once a day to patients requiring therapy for open angle glaucoma. Also disclosed are methods of promoting patient compliance, in particular geriatric and pediatric patient compliance during the therapeutic management of glaucoma using an optimal dosing regimen for forskolin to ensure the best pharmacokinetic/pharmacodynamic effects, devoid of systemic side-effects encountered with the currently used beta-blockers or prostaglandins.Type: ApplicationFiled: September 22, 2008Publication date: March 25, 2010Inventor: Muhammed Majeed
-
Publication number: 20100076006Abstract: The present invention provides for the use of combinations of drugs to treat addictive disorders.Type: ApplicationFiled: January 31, 2008Publication date: March 25, 2010Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Bankole A. Johnson, Nassima Ait-Daoud Tiouririne, Wendy J. Lynch
-
Patent number: 7683088Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.Type: GrantFiled: January 16, 2007Date of Patent: March 23, 2010Assignee: Schering CorporationInventors: Brian J. Lavey, Joseph A. Kozlowski, Guowei Zhou, Ling Tong, Wensheng Yu, Michael K. C. Wong, Bandarpalle B. Shankar, Neng-Yang Shih, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Aneta M. Micula, Seong-Heon Kim, De-Yi Yang, Razia Rizvi
-
Publication number: 20100040706Abstract: The invention relates to a cosmetic care method comprising the delivery of an effective amount of at least one cosmetically acceptable agent that activates or stimulates survivin expression in the stem cells of the basal layer of the epidermis. The invention makes it possible in particular to prevent or delay the appearance of the signs of skin aging or to treat them.Type: ApplicationFiled: June 3, 2009Publication date: February 18, 2010Applicant: LVMH RECHERCHEInventors: Marc Dumas, Frederic Bonte, Isabelle Renimel
-
Publication number: 20100041689Abstract: The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention relates the use of drugs in conjunction with behavioral intervention to treat alcohol-related diseases and disorders as well as treatment of obesity and regulating weight.Type: ApplicationFiled: December 19, 2007Publication date: February 18, 2010Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Bankole A. Johnson, Nassima Ait-Daoud Tiouririne
-
Publication number: 20100029618Abstract: Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an pan-alpha-2 adrenergic receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed.Type: ApplicationFiled: December 14, 2007Publication date: February 4, 2010Inventors: Daniel W. Gil, John E. Donello
-
Publication number: 20100022632Abstract: The present invention discloses certain diterpenes that can be used to inhibit androgen receptor activity, induce apoptosis and block cell cycle progression of androgen receptor-dependent cells. Androgen receptor has been associated with various diseases such as prostate cancer, androgeneic alopecia, breast cancer, acne etc. Accordingly, the present invention further discloses methods of treating androgen receptor-associated diseases by administering the disclosed diterpenes.Type: ApplicationFiled: July 24, 2009Publication date: January 28, 2010Inventors: Pei-Wen HSIAO, Feng-Min Lin, Sheng-Yang Wang
-
Publication number: 20100016419Abstract: The object of the present invention is to provide an antibacterial composition which has an improved antibacterial effect and a wider antibacterial spectrum than conventional antibacterial agents and which is highly safe. This object is achieved with an antibacterial composition comprising 9-(3?,7?-dimethyl-2?,6?-octadienyl)-4-hydroxy-7H-furo[3,2-?][1]benzopyran-7-one and 8-(3?,7?-dimethyl-2?,6?-octadienyl)-5-hydroxy-7-methoxy-2H-1-benzopyran-2-one.Type: ApplicationFiled: September 22, 2009Publication date: January 21, 2010Inventors: Ryo TAKEUCHI, Tadahiro Hiramoto
-
Publication number: 20100016213Abstract: A method for lowering the plasma glucose level in a subject and for treating diabetes with a diterpenoid compound.Type: ApplicationFiled: July 16, 2009Publication date: January 21, 2010Applicant: National Taiwan UniversityInventors: Shoei-Sheng Lee, Ming-Jai Su
-
Patent number: 7649014Abstract: Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.Type: GrantFiled: September 29, 2005Date of Patent: January 19, 2010Assignees: Beth Israel Deaconess Medical Center, Inc., Trustees of Boston UniversityInventors: Chen-Yu Zhang, Bradford B. Lowell, John A Porco, Jr., Ruichao Shen, Cheng T. Lin, Stefan Krauss
-
Patent number: 7649013Abstract: Administration of a modulator of cell cycle checkpoint activation, which is preferably ?-lapachone, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, protects normal cells against radiation injury. The invention includes methods of preventing radiation damage. The invention also provides methods for treating conditions such as cancer with radiotherapy, by administering a modulator of cell cycle checkpoint activation to a subject, prior to administration of radiotherapy.Type: GrantFiled: November 24, 2004Date of Patent: January 19, 2010Assignee: ArQule, Inc.Inventors: Chiang J. Li, Stephen A. Hill, YouZhi Li
-
Publication number: 20100004277Abstract: Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for identification of compounds that rescue protein trafficking defects and methods of enhancing protein production.Type: ApplicationFiled: January 26, 2007Publication date: January 7, 2010Applicant: FoldRx Pharmaceuticals, Inc.Inventors: Christine Bulawa, Michael DeVit
-
Publication number: 20100003316Abstract: The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.Type: ApplicationFiled: February 20, 2009Publication date: January 7, 2010Applicants: Duke University, ImmunolightInventors: Tuan Vo Dinh, Frederic A. Bourke, JR.
-
Publication number: 20090326607Abstract: An electrical stimulation method for the treatment of peripheral neuropathy is disclosed. In a preferred embodiment, the method utilizes an electrical stimulation device that includes a plurality of channels of electrodes each of which includes a first and second electrode positioned in electrical contact with tissue of a target region suffering from peripheral neuropathy. Agonist/antagonist muscles involved in abduction/adduction, flexion/extension, supination/pronation, protraction/retraction, and/or eversion/inversion in the peripheral body regions are stimulated with a patterned series of electrical pulses through channels of electrodes in accordance with a procedure for treating peripheral neuropathy.Type: ApplicationFiled: June 30, 2008Publication date: December 31, 2009Inventors: J. Chris Castel, Francis X. Palermo
-
Patent number: 7638554Abstract: Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) wherein R1 through R3 and R5 through R11 are defined herein, and ?, ? and ? are optional bonds, providing that when ? is absent, ? is present, and when ? is absent, ? is present. When ? is present, preferred R4 moieties are selected from O, S, NH and CH2, and when ? is absent, preferred R4 groups are selected from OH, SH, NH2 and CH3. When ? is present, the preferred R5 substituent is O, while when ? is absent, the preferred R5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.Type: GrantFiled: April 14, 2006Date of Patent: December 29, 2009Assignee: SRI InternationalInventors: Nahid Waleh, Nurulain T. Zaveri
-
Publication number: 20090312317Abstract: Coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a method for treating cancer with coumarin compounds.Type: ApplicationFiled: June 10, 2009Publication date: December 17, 2009Applicant: National Health Research InstitutesInventors: Hsing-Pang Hsieh, Jang-Yang Chang, Ching-Chuan Kuo, Yu-Sheng Chao
-
Publication number: 20090312406Abstract: A method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of one or more coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a pharmaceutical composition including a coumarin compound.Type: ApplicationFiled: June 10, 2009Publication date: December 17, 2009Inventors: Hsing-Pang Hsieh, Tsu-An Hsu, Jiann-Yih Yeh, Jim-Tong Horng, Shin-Ru Shih, Sui-yuan Chang, Yu-Sheng Chao
-
Publication number: 20090304789Abstract: The present invention is drawn to novel topiramate compositions as well as methods for treating obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention also features a pharmaceutical composition that includes, e.g., topiramate alone or in combination with a sympathomimetic agent and a novel escalating dosing strategy for administering such compositions.Type: ApplicationFiled: June 9, 2008Publication date: December 10, 2009Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20090304785Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: ApplicationFiled: June 9, 2009Publication date: December 10, 2009Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20090306197Abstract: The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: March 7, 2007Publication date: December 10, 2009Applicant: Bayer Healthcare AGInventors: Carsten Schmeck, Hilmar Bischoff, Volkhart Li, Klemens Lustig, Michael Thutewohl, Alexandros Vakalopoulos, Olaf Weber
-
Publication number: 20090298930Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.Type: ApplicationFiled: November 18, 2005Publication date: December 3, 2009Inventors: Arie L. Gutman, Gennady A. Nisnevich, Igor Rukhman, Boris Tishin, Marina Etinger, Irina Fedotev, Boris Pertsikov, Ram Khanolkar
-
Publication number: 20090298931Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.Type: ApplicationFiled: October 4, 2007Publication date: December 3, 2009Applicant: BIONOMICS LIMITEDInventors: Bernard Luke Flynn, Jonathan B. Baell, Andrew J. Harvey, Jason Hugh Chaplin, Dharam Paul, Jorgen Alvar Mould
-
Publication number: 20090292012Abstract: A therapeutic agent or prophylactic agent for a disease requiring an anti-foaming action for a cell and/or an inhibitory action for acyl-CoA cholesterol acyltransferase in treatment or prevention, characterized in that the therapeutic agent or prophylactic agent comprises as an effective ingredient a processed product derived from Peucedanum japonicum.Type: ApplicationFiled: January 26, 2006Publication date: November 26, 2009Inventors: Tatsuji Enoki, Yoko Kudo, Katsumi Sugiyama, Hiromu Ohnogi, Hiroaki Sagawa, Ikunoshin Kato
-
Publication number: 20090285797Abstract: The invention relates to methods and compositions for regulating nicotine metabolism. Also provided are methods for screening and assessing substances for regulating nicotine metabolism. Methods are provided for assessing nicotine metabolism.Type: ApplicationFiled: September 25, 2008Publication date: November 19, 2009Applicant: Nicogen Inc.Inventors: Edward M. Sellers, Rachel F. Tyndale
-
Publication number: 20090285759Abstract: A drug comprises an organic or inorganic compound, and is made magnetic by modification of side chains and/or crosslinking between side chains.Type: ApplicationFiled: August 23, 2006Publication date: November 19, 2009Inventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Patent number: 7618997Abstract: A compound represented by the following formula (I): wherein R1 and R2 represent amino groups that substitute at adjacent positions on the phenyl ring, provided that either of R1 and R2 represents a mono(C1-6 alkyl)-substituted amino group and the other represents an unsubstituted amino group; and R3 and R4 independently represent hydrogen atom or an acyl group, and an agent for measurement of nitrogen monoxide which comprises said compound.Type: GrantFiled: May 8, 2006Date of Patent: November 17, 2009Assignees: Sekisui Medical Co., Ltd.Inventors: Tetsuo Nagano, Hirotatsu Kojima
-
Publication number: 20090269426Abstract: This invention relates to combinations of vasoactive substances which are useful in the treatment of sexual dysfunctions associated with poor local blood supply and/or insufficient lubrication. The active compounds are selected from a:—esculoside or visnadine;—forskolin or extracts containing it, or alternatively, purified lipophilic extracts of plants of the genus Ipomea;—esters of ximenynic acid;—optionally, at least one compound selected from a icarin or derivatives or extracts thereof which contain it, amentoflavone, and Gingko biloba dimeric flavones. The combination of these vasoactive substances is incorporated in gels and lotions designed to be applied to the genital organs. These formulations are useful in inducing erection of the male and female sex organs and enhancing orgasm and sexual performance. The formulations are particularly useful in the treatment of female sexual dysfunctions.Type: ApplicationFiled: July 1, 2009Publication date: October 29, 2009Applicant: INDENA S.P.A.Inventor: Ezio BOMBARDELLI
-
Patent number: 7601754Abstract: Novel flavonoid compounds having anti-oxidant activity are described. Formula 1. The compounds have been shown to exhibit anti-oxidative properties in biological systems and their utility in a sunscreen or skincare composition or to treat conditions involving oxidative damage, especially curative or prophylactic treatment of Alzheimer's disease or ischaemia-reperfusion injury, is described.Type: GrantFiled: July 14, 2003Date of Patent: October 13, 2009Assignee: Antoxis LimitedInventors: Stuart Thomas Caldwell, Christopher James Bennett, Richard Charles Hartley, Donald Barton McPhail, Garry Graeme Duthie
-
Publication number: 20090247620Abstract: The present invention relates to benzochromene derivatives of the formula I where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in TN, OCB, LCOS and/or IPS-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as therapeutic active ingredients.Type: ApplicationFiled: December 5, 2006Publication date: October 1, 2009Inventors: Andreas Taugerbeck, Elvira Montenegro, Atsutaka Manabe, Herbert Plach
-
Publication number: 20090239942Abstract: The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.Type: ApplicationFiled: March 19, 2009Publication date: September 24, 2009Inventor: James C. CLOYD
-
Patent number: 7592328Abstract: The present invention is directed to the novel use of complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of ?-CD, ?-CD and ?-CD and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrahydrocannabinol and cannabidiol.Type: GrantFiled: February 20, 2003Date of Patent: September 22, 2009Assignee: Pedipharm OyInventors: Pekka Jarho, Janne Mannila, Tomi Järvinen
-
Publication number: 20090233997Abstract: The present invention relates to a composition for promoting collagen synthesis and a composition for external application to skin which includes the collagen synthesis promoting composition. The collagen synthesis promoting composition includes, as an effective component, at least one selected from the group consisting of compounds represented as: wherein R is hydrogen, a methoxy group, or a 3-methyl-2-butenyl group. The composition for external application to skin includes at least one collagen synthesis promoting component selected from the group consisting of compounds represented by above.Type: ApplicationFiled: March 17, 2009Publication date: September 17, 2009Applicant: LG HOUSEHOLD & HEALTH CARE, LTD.Inventors: Mu-Hyun JIN, Sang-Hwa Lee, Yang-Mi Park, Sang-Jin Kang
-
Patent number: 7589083Abstract: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.Type: GrantFiled: July 19, 2006Date of Patent: September 15, 2009Assignee: Cancure Laboratories, LLCInventor: Zoltan Kiss
-
Publication number: 20090226551Abstract: A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.Type: ApplicationFiled: March 7, 2008Publication date: September 10, 2009Inventors: Chao Hsiang CHEN, Mei-Yin Chien, Wen-Mei Fu, Jin-Ming Chang
-
Patent number: 7585985Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.Type: GrantFiled: August 1, 2008Date of Patent: September 8, 2009Assignee: Eli Lilly and CompanyInventors: Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
-
Patent number: 7585893Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.Type: GrantFiled: April 28, 2005Date of Patent: September 8, 2009Assignee: Cancer Research Technology LimitedInventors: Bruce Charles Baguley, Lai-Ming Ching, Philip Kestell, Liangli Zhao
-
Publication number: 20090221693Abstract: The present invention refers to compounds of the general formulae I as defined above, preferably ?-mangostin, for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function and endurance. Other fields of use are eating disorders such as bulimia and anorexia nervosa, use for accelerating wound healing, and/or use for the treatment/prevention of bone disorders such as osteoporosis and osteopenia.Type: ApplicationFiled: May 2, 2007Publication date: September 3, 2009Inventors: Daniel D'Orazio, Daniel Raederstorff, Goede Schueler, Ying Wang-Schmidt, Swen Wolfram
-
Publication number: 20090216317Abstract: An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.Type: ApplicationFiled: March 22, 2006Publication date: August 27, 2009Inventors: Keith R. Cromack, John L. Toner, Sandra E. Burke, Richard W. Krasula, Lewis B. Schwartz
-
Publication number: 20090215687Abstract: The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine aType: ApplicationFiled: October 20, 2006Publication date: August 27, 2009Applicant: CORNELL RESEARCH FOUNDATION, INC.Inventors: Rajiv R. Ratan, Ambreena Siddiq, Juan C. Chavez
-
Patent number: 7576124Abstract: Safe, effective first-pass inhibiting compounds and citrus-derived substances are provided. Formulations containing the compounds are also provided as are methods for their preparation and for inhibiting the first pass effect.Type: GrantFiled: May 11, 2007Date of Patent: August 18, 2009Assignee: Bioavailability Systems, L.L.C.Inventor: James W. Harris
-
Patent number: 7576123Abstract: Compositions, methods, etc. for addressing the first-pass effect.Type: GrantFiled: April 4, 2007Date of Patent: August 18, 2009Assignee: Bioavailability Systems, L.L.C.Inventor: James W. Harris
-
Publication number: 20090203669Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: November 13, 2006Publication date: August 13, 2009Inventor: Nicholas E. Goeders
-
Publication number: 20090203725Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors and/or modulate the amount of androgen receptors; and to methods for making and using such compounds. Also provided are compositions containing such compounds and methods for making and using such compositions.Type: ApplicationFiled: December 21, 2006Publication date: August 13, 2009Inventors: Cornelis Arjan Van Oeveren, Yixing Shen, Shuo Zhao, Lin Zhi
-
Publication number: 20090192120Abstract: The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP.Type: ApplicationFiled: June 24, 2008Publication date: July 30, 2009Applicant: MUSC Foundation for Research DevelopmentInventor: Inderjit Singh